The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform

Wade L Thorstad - One of the best experts on this subject based on the ideXlab platform.

Linda Feeley - One of the best experts on this subject based on the ideXlab platform.

  • Tumour Cell Anaplasia and Multinucleation as Prognosticators in Oropharyngeal Squamous Cell Carcinoma
    Head and Neck Pathology, 2019
    Co-Authors: Peter Molony, Reiltin Werner, Cynthia Heffron, Deirdre Callanan, Cara Martin, Patrick Sheahan, Linda Feeley
    Abstract:

    Human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinomas (OPSCC) tend to have good outcomes, however a subset does not share this favourable prognosis. The aim of this paper is to investigate the utility of tumour cell Anaplasia and multinucleation as prognostic markers in oropharyngeal squamous cell carcinoma. Retrospective review of 104 patients with OPSCC or squamous cell carcinoma of unknown primary site (SCCUP) who underwent primary resection and/or lymph node dissection. Slides of both primary and nodal metastatic disease were assessed for the presence of Anaplasia and multinucleation. 53 patients were HPV-positive. Anaplasia was more frequent in males (p = 0.005), smokers (p = 0.003), and HPV-negative disease (p = 0.04). HPV status and > 10 pack-year smoking history were independent predictors of recurrence-free survival (RFS) and disease-specific survival (DSS). Neither Anaplasia, nor multinucleation, at the primary site or in cervical metastases, had any significant impact on RFS or DSS. We did not find either Anaplasia or multinucleation to have any significant prognostic impact in OPSCC. However, given the small number of adverse events in the HPV-positive cohort, we may have lacked sufficient power to detect significance in what was the subgroup of primary interest. Our study highlights the challenge of identifying markers of poor prognosis in HPV-positive OPSCC.

James S Lewis - One of the best experts on this subject based on the ideXlab platform.

Paul E Grundy - One of the best experts on this subject based on the ideXlab platform.

  • molecular profiling reveals frequent gain of mycn and Anaplasia specific loss of 4q and 14q in wilms tumor
    Genes Chromosomes and Cancer, 2011
    Co-Authors: Richard D Williams, Reem Alsaadi, Rachael Natrajan, Alan Mackay, Tasnim Chagtai, Suzanne E Little, Sandra Hing, Kerry Fenwick, Alan Ashworth, Paul E Grundy
    Abstract:

    Anaplasia in Wilms tumor, a distinctive histology characterized by abnormal mitoses, is associated with poor patient outcome. While anaplastic tumors frequently harbour TP53 mutations, little is otherwise known about their molecular biology. We have used array comparative genomic hybridization (aCGH) and cDNA microarray expression profiling to compare anaplastic and favorable histology Wilms tumors to determine their common and differentiating features. In addition to changes on 17p, consistent with TP53 deletion, recurrent Anaplasia-specific genomic loss and under-expression were noted in several other regions, most strikingly 4q and 14q. Further aberrations, including gain of 1q and loss of 16q were common to both histologies. Focal gain of MYCN, initially detected by high resolution aCGH profiling in 6/61 anaplastic samples, was confirmed in a significant proportion of both tumor types by a genomic quantitative PCR survey of over 400 tumors. Overall, these results are consistent with a model where Anaplasia, rather than forming an entirely distinct molecular entity, arises from the general continuum of Wilms tumor by the acquisition of additional genomic changes at multiple loci. (C) 2011 Wiley Periodicals, Inc.

  • bilateral wilms tumor with Anaplasia lessons from the national wilms tumor study
    Journal of Pediatric Surgery, 2006
    Co-Authors: Thomas E Hamilton, Daniel M Green, Elizabeth J Perlman, Pedram Argani, Paul E Grundy, Michael L Ritchey, Robert C Shamberger
    Abstract:

    Abstract Purpose The purpose of this study was to evaluate whether initial diagnostic technique influenced the ability to identify anaplastic histology, to determine the time interval to diagnosis of Anaplasia, and to delineate the incidence of discordant pathology in bilateral Wilms' tumor. We hypothesized that delay in diagnosis of Anaplasia could affect time to appropriate surgery and intensive multimodality therapy. Methods One hundred eight-nine children were enrolled in the fourth National Wilms' Tumor Study with synchronous bilateral tumors, 27 of whom were eventually shown to have anaplastic histology. Initial diagnostic technique, time interval to diagnosis of Anaplasia, and the incidence of discordant pathology were determined. Results Anaplasia was identified in 0 of 7 tumors by core needle biopsy, 3 of 9 tumors by open wedge biopsy, and in 7 of 9 cases by partial or complete nephrectomy. The mean duration of first chemotherapy regimen (DD or EE) was 20, 39, and 36 weeks, respectively, before Anaplasia was identified at second surgery. Discordant pathology between bilateral tumors was identified on final tissue diagnosis in 20 patients. Only 4 patients had anaplastic tumors in both kidneys. Conclusions Core needle biopsy did not identify Anaplasia in 7 of 7 children. Open biopsy or partial/complete nephrectomy identified Anaplasia at initial diagnostic procedure in 10 of 18 children. Twenty of 24 patients at final tissue diagnosis had discordant pathology between the 2 kidneys. Earlier interval incisional biopsy or resection may identify anaplastic histology and limit the duration of chemotherapy targeted to favorable histology for children with bilateral Wilms' tumor and Anaplasia.

  • Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Journal of Clinical Oncology, 1994
    Co-Authors: Daniel M Green, Paul E Grundy, Paulo Faria, J B Beckwith, N. E. Breslow, Jami Moksness, Jerry Z. Finklestein, Patrick R. M. Thomas, Stephen J. Shochat
    Abstract:

    PURPOSETo evaluate the effect of the combination of vincristine, dactinomycin, and doxorubicin with (regimen J) or without (regimen DD-RT) cyclophosphamide on the relapse-free survival of children with stages II to IV Wilms' tumor and focal or diffuse Anaplasia.PATIENTS AND METHODSWe reviewed the clinical courses of all randomized patients from National Wilms' Tumor Study (NWTS)-3 and NWTS-4 with stages II to IV anaplastic Wilms' tumor, and determined the 4-year relapse-free survival rate separately for those with focal or diffuse Anaplasia. Anaplasia was evaluated using newly developed topographic definitions for focal and diffuse Anaplasia.RESULTSThe 4-year relapse-free survival rate for five children with focal Anaplasia who received regimen DD-RT was 80.0%, compared with 100.0% for eight children who received regimen J (P = .68). The 4-year relapse-free survival rate for 29 children with diffuse Anaplasia treated with regimen DD-RT was 27.2%, compared with 54.8% for 30 children treated with regimen J ...

Peter Molony - One of the best experts on this subject based on the ideXlab platform.

  • Tumour Cell Anaplasia and Multinucleation as Prognosticators in Oropharyngeal Squamous Cell Carcinoma
    Head and Neck Pathology, 2019
    Co-Authors: Peter Molony, Reiltin Werner, Cynthia Heffron, Deirdre Callanan, Cara Martin, Patrick Sheahan, Linda Feeley
    Abstract:

    Human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinomas (OPSCC) tend to have good outcomes, however a subset does not share this favourable prognosis. The aim of this paper is to investigate the utility of tumour cell Anaplasia and multinucleation as prognostic markers in oropharyngeal squamous cell carcinoma. Retrospective review of 104 patients with OPSCC or squamous cell carcinoma of unknown primary site (SCCUP) who underwent primary resection and/or lymph node dissection. Slides of both primary and nodal metastatic disease were assessed for the presence of Anaplasia and multinucleation. 53 patients were HPV-positive. Anaplasia was more frequent in males (p = 0.005), smokers (p = 0.003), and HPV-negative disease (p = 0.04). HPV status and > 10 pack-year smoking history were independent predictors of recurrence-free survival (RFS) and disease-specific survival (DSS). Neither Anaplasia, nor multinucleation, at the primary site or in cervical metastases, had any significant impact on RFS or DSS. We did not find either Anaplasia or multinucleation to have any significant prognostic impact in OPSCC. However, given the small number of adverse events in the HPV-positive cohort, we may have lacked sufficient power to detect significance in what was the subgroup of primary interest. Our study highlights the challenge of identifying markers of poor prognosis in HPV-positive OPSCC.